On 26 July 2012, the Management Board of Krka, d. d. held a press conference toopresent to the public the results of the Krka Group and Krka Company for the first half of 2012.
The Group sold EUR 565.3 million worth of products and services in the first half of 2012, up EUR 36.5 million, or 7%, compared to the same period last year. Sales in markets outside Slovenia, which represent 92% of the Group's total sales, were up EUR 41.1 million, or 9%, compared to the same period last year.
The Krka Company sales amounted to EUR 521.3 million, up EUR 32.6 million, or 7%, compared to the same period last year.
Krka's leading sales region is Region East Europe, where Krka generated 30% of its total sales. The highest relative as well as absolute sales growth among all Krka regions was recorded in this region, where sales in the first half of the year amounted to EUR 167.9 million, an increase by 25%. Region East Europe includes Krka's largest individual market, the Russian Federation, where sales amounted to EUR 114.9 million, up 24% compared to the same period last year.
The Krka Group sold EUR 473.7 million worth of prescription pharmaceuticals in the first half of 2012, 8% more than in the same period last year. Prescription pharmaceuticals represent 84% of total Krka Group sales. Sales of prescription pharmaceuticals increased the most in Region East Europe (up 30%), Region West Europe and Overseas Markets (up 24%) and Region South-East Europe (up 6%), while in Region Central Europe and Region Slovenia sales were down compared to the same period last year.
The Group recorded EUR 117.1 million of operating profit, down 5% compared to the same period last year. Pre-tax profit amounted to EUR 108.5 million, down 8% compared to the same period last year. The Group generated EUR 90.1 million of profit after tax in the first half of the year, down barely 3% from last year's profit for the period. The Krka Company generated EUR 82.9 million of profit, down one tenth.
The Group’s profit margin was 15.9% (Krka Company 15.9%), the EBIT margin 20.7% (19.6%) and the EBITDA margin 28.5% (26.2%). ROE at Group level was 15.2% (Krka Company 14.1%), with ROA at 11.4% (11.0%).